A Comprehensive Monograph on Tizanidine (DB00697): Pharmacology, Clinical Utility, and Safety Profile

Executive Summary

Tizanidine is a centrally acting alpha-2 (α2​) adrenergic receptor agonist, classified as a skeletal muscle relaxant, with a chemical structure analogous to the antihypertensive agent clonidine.[1] Its sole indication approved by the U.S. Food and Drug Administration (FDA) is for the management of muscle spasticity, a condition of heightened muscle tone and involuntary spasms arising from neurological disorders such as multiple sclerosis, spinal cord injury, stroke, and traumatic brain injury.[3] The therapeutic action of tizanidine is mediated through its agonistic activity at

α2​-adrenergic receptors within the central nervous system, which enhances the presynaptic inhibition of spinal motor neurons. This is achieved primarily by reducing the release of excitatory amino acids, including glutamate and aspartate, which are key drivers of muscle hypertonicity.[3]

The clinical utility of tizanidine is defined by its distinct pharmacokinetic and pharmacodynamic profile. It is a short-acting agent, with therapeutic effects peaking approximately 1 to 2 hours after oral administration and dissipating within 3 to 6 hours.[6] This characteristic positions tizanidine as a treatment for intermittent, "as-needed" relief of spasticity to facilitate specific daily activities, rather than for providing continuous, basal muscle relaxation.[3] Its clinical efficacy is comparable to that of other antispasticity agents like baclofen and diazepam, with some evidence suggesting a more tolerable side-effect profile.[1] The most common dose-limiting adverse effects are sedation, dizziness, and dry mouth, which are direct extensions of its pharmacological activity.[1]

A paramount consideration in the clinical use of tizanidine is its extensive hepatic metabolism, which is almost exclusively mediated by the cytochrome P450 isoenzyme CYP1A2.[1] This metabolic dependency creates a significant vulnerability to drug-drug interactions. Co-administration with potent inhibitors of CYP1A2, such as the antidepressant fluvoxamine or the antibiotic ciprofloxacin, is strictly contraindicated. Such combinations can dramatically increase tizanidine plasma concentrations—by as much as 33-fold—leading to severe and potentially life-threatening adverse events, including profound hypotension, bradycardia, and excessive sedation.[1] Therefore, meticulous medication reconciliation and a thorough understanding of its metabolic pathway are essential for the safe and effective use of tizanidine.

Chemical Identity and Physicochemical Properties

A precise understanding of a drug's chemical and physical nature is fundamental to its study and clinical application. Tizanidine is a well-characterized small molecule with a unique heterocyclic structure that defines its pharmacological activity.

Nomenclature and Identifiers

Tizanidine is identified across scientific literature, regulatory databases, and chemical registries by a standardized set of names and codes. This ensures unambiguous reference and facilitates data retrieval and cross-referencing. The primary generic name for the active pharmaceutical ingredient is tizanidine.[1] Its unique Chemical Abstracts Service (CAS) Registry Number is 51322-75-9.[1] According to the International Union of Pure and Applied Chemistry (IUPAC) nomenclature, its systematic name is 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine.[1] The molecule is also known by other chemical names, including 5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole, and was referred to by the developmental code DS 103-282.[3]

Its molecular formula is C9​H8​ClN5​S, corresponding to a molecular weight of 253.71 g/mol.[10] For computational and cheminformatics purposes, it is represented by the International Chemical Identifier (InChI)

InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13) and the Simplified Molecular Input Line Entry System (SMILES) string C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl.[1] A comprehensive list of identifiers is provided in Table 1.

Table 1: Tizanidine - Key Chemical and Drug Identifiers

Identifier Type	Value	Source(s)
DrugBank ID	DB00697	1
CAS Number	51322-75-9	1
IUPAC Name	5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine	1
UNII	6AI06C00GW	1
PubChem CID	5487	1
ChEMBL ID	CHEMBL1079	1
ATC Code	M03BX02	1
InChIKey	XFYDIVBRZNQMJC-UHFFFAOYSA-N	1

Chemical Structure and Classification

Tizanidine is classified as a small molecule drug.[3] Its core structure is a 2,1,3-benzothiadiazole heterocyclic system, which is substituted at the C-4 position with a

Δ(1)-imidazolin-2-ylamino group and at the C-5 position with a chloro group.[10] The presence of the imidazoline ring is a key structural feature that it shares with clonidine, another prominent

α2​-adrenergic agonist, which accounts for their similar mechanisms of action.[1] This structural relationship is central to understanding both the therapeutic effects and the side-effect profile of tizanidine.

Physicochemical Properties

In its solid state, tizanidine hydrochloride, the salt form used in pharmaceutical preparations, is a white to off-white or pale yellow, fine crystalline powder.[8] It is described as being odorless or having a faint characteristic odor.[8] Tizanidine exhibits slight solubility in water and is soluble in organic solvents such as dimethyl sulfoxide (DMSO).[8] These properties influence its formulation into oral dosage forms and its behavior in biological systems.

Synthesis Overview

The chemical synthesis of tizanidine was first reported in a patent and involves a multi-step process. The synthesis begins with 4-chlorophenylenediamine, which is converted over three steps into a key intermediate, 5-chloro-2,1,3-benzothiadiazol-4-amine. This intermediate is formed by treating the precursor with thionyl chloride to create the benzothiadiazole heterocycle, followed by nitration and subsequent reduction steps. This intermediate is then further reacted to yield the final tizanidine molecule.[1]

Clinical Pharmacology

The clinical effects of tizanidine are a direct result of its interactions with specific receptors in the central nervous system and its subsequent physiological consequences. A detailed examination of its mechanism of action and pharmacodynamic effects is essential for its rational clinical use.

Mechanism of Action: A Central α2-Adrenergic Agonist

The primary mechanism of action of tizanidine is its function as a potent agonist at central α2​-adrenergic receptors.[1] While these receptors are found throughout the body, the myotonolytic (muscle-relaxing) effects of tizanidine are principally mediated by its action on

α2​ receptors located presynaptically on neurons within the spinal cord.[2]

Activation of these spinal α2​ receptors by tizanidine initiates an intracellular signaling cascade that results in the inhibition of adenylyl cyclase, leading to a decrease in cyclic adenosine monophosphate (cAMP) levels and subsequent modulation of ion channel activity. The ultimate effect of this signaling is an increase in presynaptic inhibition of motor neurons.[3] Tizanidine achieves this by suppressing the release of excitatory amino acid neurotransmitters, primarily glutamate and aspartate, from the terminals of spinal interneurons.[4] These excitatory amino acids are responsible for transmitting signals that cause motor neurons to fire, leading to muscle contraction. By dampening this excitatory input, tizanidine reduces the overall facilitation of spinal motor neurons, which directly translates to a decrease in muscle hypertonicity and the relief of spasticity.[4]

A key feature of tizanidine's action is its preferential effect on polysynaptic pathways within the spinal cord, which involve multiple interneurons relaying signals to motor neurons.[2] This selectivity contrasts with a weaker effect on monosynaptic reflexes (direct sensory-to-motor neuron communication), contributing to its specific profile as an antispasticity agent. Importantly, tizanidine exerts no direct effects on skeletal muscle fibers or at the neuromuscular junction, confirming its centrally mediated mechanism.[3]

Pharmacodynamics: Myotonolytic and Systemic Effects

The interaction of tizanidine with its target receptors produces a range of measurable physiological effects, both desired and undesired.

Muscle Relaxation (Myotonolytic Effect)

The principal pharmacodynamic outcome of tizanidine administration is the reduction of skeletal muscle tone. Clinically, this manifests as a decrease in spasticity, clonus (rapid, involuntary muscle contractions), and resistance to passive movement.[3] By alleviating these symptoms, tizanidine can improve mobility and, in some cases, increase the strength of voluntary movement, thereby facilitating daily activities and physical therapy.[3]

Antinociceptive and Anticonvulsant Properties

The same underlying mechanism of α2​-receptor-mediated inhibition of central neuronal activity is believed to confer secondary pharmacodynamic properties. Animal models and some clinical observations suggest that tizanidine possesses antinociceptive (pain-relieving) and anticonvulsant activities.[2] These effects contribute to its utility in managing painful muscle spasms and its off-label use in certain pain syndromes.

Cardiovascular Effects

Tizanidine's structural similarity to clonidine, a potent antihypertensive agent, results in a shared capacity to influence the cardiovascular system.[1] However, a critical pharmacodynamic distinction underpins tizanidine's clinical utility. Pharmacological studies have established that tizanidine possesses only one-tenth to one-fiftieth (

1/10 to 1/50) of the blood pressure-lowering potency of clonidine.[1] This separation of effects represents a significant therapeutic advantage, allowing for the achievement of effective muscle relaxation at doses that produce only mild and transitory cardiovascular effects compared to clonidine. This pharmacodynamic profile suggests that tizanidine was successfully developed as a clonidine analog that retains the desired central nervous system effects of

α2​-agonism while minimizing the potent and often dose-limiting hypotensive activity. Despite this relative cardiovascular safety, tizanidine can still cause clinically relevant, dose-dependent hypotension and bradycardia, which remain important considerations in its clinical use.[3] Abrupt withdrawal can also lead to rebound hypertension and tachycardia.[3]

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of tizanidine—how the body absorbs, distributes, metabolizes, and excretes the drug—is fundamental to understanding its clinical behavior, including its dosing regimen, duration of action, and potential for drug interactions. This profile is characterized by rapid absorption, extensive first-pass metabolism, and a short half-life, which collectively define its therapeutic niche.

Absorption and Bioavailability

Following oral administration, tizanidine is rapidly and essentially completely absorbed from the gastrointestinal tract.[7] However, the drug is subject to extensive first-pass metabolism in the liver. This presystemic elimination process significantly reduces the amount of active drug that reaches the systemic circulation, resulting in an absolute oral bioavailability of only approximately 40%.[1]

The absorption of tizanidine is significantly influenced by the presence of food, and this effect is complex and differs between the tablet and capsule formulations. This distinction is clinically critical.

• Tablets: When a 4 mg tablet is administered with food, the mean maximum plasma concentration (Cmax​) is increased by approximately 30%, and the median time to reach this peak concentration (Tmax​) is delayed by about 25 minutes (to 1 hour and 25 minutes).[8]
• Capsules: In contrast, when a 4 mg capsule is administered with food, the mean Cmax​ is decreased by 20%, and the median Tmax​ is substantially delayed by 2 to 3 hours.[8]
• Capsule Contents: If the contents of a capsule are sprinkled on soft food (e.g., applesauce), both the Cmax​ and the area under the concentration-time curve (AUC) are increased by 15-20% compared to taking an intact capsule on an empty stomach.[6]

These formulation-dependent food effects mean that tablets and capsules are not bioequivalent under fed conditions and should not be interchanged without clinical consideration and potential dose adjustment.[6]

Distribution

Once in the systemic circulation, tizanidine is extensively distributed throughout the body. This is reflected by its large mean steady-state volume of distribution, which is 2.4 L/kg following intravenous administration.[1] Tizanidine exhibits low binding to plasma proteins, with only about 30% of the drug being bound.[1] This low protein binding suggests that a large fraction of the drug is free and available to distribute into tissues and exert its pharmacological effect.

Metabolism

Metabolism is the primary route of elimination for tizanidine. Approximately 95% of an administered dose is cleared via metabolism, which occurs predominantly in the liver.[1] The biotransformation of tizanidine is almost exclusively mediated by a single cytochrome P450 isoenzyme:

CYP1A2.[1] This heavy reliance on a single metabolic pathway is the most critical aspect of tizanidine's pharmacokinetic profile, as it renders the drug highly susceptible to interactions with other substances that inhibit or induce this enzyme. The metabolites produced from tizanidine are not known to be pharmacologically active.[7]

Excretion

Tizanidine and its metabolites are eliminated from the body primarily through renal excretion. On average, 60% of the total radioactivity from a radiolabeled dose is recovered in the urine, with an additional 20% recovered in the feces.[1]

The elimination half-life of the parent tizanidine molecule is short, approximately 2.5 hours.[1] This short half-life is directly responsible for the drug's short duration of clinical effect. In stark contrast, its inactive metabolites have much longer elimination half-lives, ranging from 20 to 40 hours, though this is of limited clinical significance given their lack of activity.[1] The combination of a short parent drug half-life and extensive, single-pathway metabolism creates a distinct clinical profile. It allows for targeted, short-term relief but simultaneously creates a significant vulnerability to metabolic inhibition, necessitating careful patient management regarding food intake, formulation consistency, and concomitant medications.

Table 2: Summary of Key Pharmacokinetic Parameters for Tizanidine

Pharmacokinetic Parameter	Value/Description	Source(s)
Absorption
Bioavailability (Absolute Oral)	~40%	1
Tmax​ (Tablets, Fasted)	~1 hour	8
Tmax​ (Tablets, Fed)	~1 hour 25 minutes (delayed by 25 min)	8
Cmax​ (Tablets, Fed)	Increased by ~30%	8
Tmax​ (Capsules, Fed)	Delayed by 2-3 hours	8
Cmax​ (Capsules, Fed)	Decreased by ~20%	8
Distribution
Volume of Distribution (Vd​)	2.4 L/kg	1
Protein Binding	~30%	1
Metabolism
Extent of Metabolism	~95% of dose	1
Primary Metabolic Enzyme	Cytochrome P450 1A2 (CYP1A2)	1
Metabolites	Inactive	7
Excretion
Elimination Half-life (Tizanidine)	~2.5 hours	1
Elimination Half-life (Metabolites)	20–40 hours	1
Route of Excretion	Urine (~60%), Feces (~20%)	1

Therapeutic Applications and Clinical Efficacy

Tizanidine's unique pharmacological profile has established its role in treating spasticity, while also prompting investigation and use in a variety of other conditions.

FDA-Approved Indication: Management of Spasticity

The sole indication for which tizanidine has received FDA approval is the management of spasticity.[4] Spasticity is a debilitating motor disorder, secondary to upper motor neuron lesions, characterized by a velocity-dependent increase in tonic stretch reflexes (muscle tone) and exaggerated tendon jerks, resulting from hyperexcitability of the stretch reflex.[3] Tizanidine is effective for treating spasticity regardless of its etiology, including cases arising from multiple sclerosis (MS), spinal cord injury, stroke, acquired brain injury, amyotrophic lateral sclerosis (ALS), and spastic cerebral palsy.[1]

Because of its short duration of action, product labeling specifically recommends that treatment with tizanidine be reserved for those daily activities and times when relief of spasticity is most important to the patient, such as before physical therapy, transfers, or personal care.[3]

Clinical Efficacy

Adequate and well-controlled clinical studies have confirmed the efficacy of tizanidine in reducing increased muscle tone associated with spasticity.[8] Its effectiveness has been shown to be comparable to that of other first-line antispasmodic agents, including baclofen and diazepam.[1] A notable advantage highlighted in some comparisons is that tizanidine may be better tolerated than baclofen and diazepam, potentially offering a more favorable balance between efficacy and side effects for some patients.[1]

Off-Label and Investigational Uses

Despite its single FDA-approved indication, tizanidine is widely prescribed for a variety of off-label uses, with some estimates suggesting that such prescriptions may account for up to 40% of its total use.[24] This broad application stems from its muscle relaxant, antinociceptive, and sedative properties.

• Musculoskeletal Pain: Tizanidine is frequently used for the short-term management of acute and chronic non-spastic musculoskeletal pain, such as low back pain and neck pain, often as an adjunct to nonsteroidal anti-inflammatory drugs (NSAIDs).[4]
• Headaches: The drug is used off-label for the management of chronic migraine headaches and tension-type headaches.[4] It is also employed as part of a detoxification strategy for patients with analgesic rebound headaches, where it can help manage withdrawal symptoms.[4]
• Other Conditions: A range of other off-label applications have been reported. These include the management of pain and muscle spasms associated with fibromyalgia, regional myofascial pain syndromes, and refractory insomnia, particularly in patients whose sleep is disrupted by spasticity.[4] Its potential anticonvulsant properties have also been noted.[4]

Clinical Trial Synopsis

The clinical evidence base for tizanidine has been expanded through numerous post-marketing studies that have explored its efficacy and safety in various contexts, including direct comparisons with other therapies.

• NCT00430196: This completed Phase 4 clinical trial directly compared the efficacy of oral tizanidine (Zanaflex®) against localized injections of onabotulinumtoxinA (BOTOX®) for the treatment of upper limb spasticity following a stroke or traumatic brain injury. Such trials are crucial for defining the relative roles of systemic versus localized treatments for focal spasticity.[26]
• NCT03068897: A completed Phase 4 trial investigated a common clinical scenario: the treatment of acute low back pain. It evaluated the effectiveness of adding a muscle relaxant (metaxalone, tizanidine, or baclofen) to a baseline therapy of ibuprofen, providing data on the potential synergistic benefits of such combinations.[27]
• NCT02403687 (PACE Study): The Prospective Analgesic Compound Efficacy study was a broader investigation into the effectiveness of several analgesic medications, including tizanidine, for a variety of acute pain conditions such as arthritis, headache, gout flares, and muscle spasms.[28]

Dosing, Formulations, and Administration

The safe and effective use of tizanidine requires careful attention to its available formulations, dosing and titration schedules, and specific administration guidelines, particularly concerning food effects and discontinuation.

Available Formulations and Strengths

Tizanidine is commercially available for oral administration in two primary formulations:

• Oral Tablets: Typically supplied in 2 mg and 4 mg strengths. The 4 mg tablets are often quadrisected (scored into four sections), allowing for dose flexibility.[7]
• Oral Capsules: Available in 2 mg, 4 mg, and 6 mg strengths.[7]

Dosing and Titration

The dosing of tizanidine must be individualized to balance the therapeutic benefit of spasticity reduction against the potential for adverse effects, primarily sedation and hypotension.

• Initial Dose: The recommended starting dose for adults is 2 mg taken orally.[7]
• Frequency: Because the drug's effects peak at 1-2 hours and dissipate within 3-6 hours, doses can be repeated at 6- to 8-hour intervals as needed. The frequency should not exceed three doses in a 24-hour period.[7]
• Titration: To achieve an optimal clinical response, the dose should be titrated upwards slowly. Dosage can be increased in increments of 2 mg to 4 mg per dose, with at least 1 to 4 days between each dose escalation to allow the patient to acclimate.[7]
• Maximum Dose: The total daily dose should not exceed 36 mg. Single doses greater than 16 mg have not been systematically studied and are not recommended.[7]

Administration Guidelines

Proper administration is crucial for ensuring consistent therapeutic effects and minimizing variability in drug exposure.

• Consistency with Food: As detailed in the Pharmacokinetics section, food has a complex and formulation-dependent impact on tizanidine absorption. Therefore, a critical counseling point for patients is the need for consistency: the medication should be taken either always with food or always without food. Altering this pattern can lead to unexpected changes in drug levels, potentially affecting both efficacy and tolerability.[6]
• Formulation Switching: Due to the significant pharmacokinetic differences between tablets and capsules in the fed state, these formulations are not bioequivalent and should not be considered interchangeable. Clinicians must exercise caution and provide clear instructions to the patient if a switch between formulations is necessary.[6]
• Administration of Capsules: For patients who have difficulty swallowing, the capsules can be opened and the entire contents sprinkled onto a small amount of soft food, such as applesauce, and consumed immediately.[1]

Discontinuation of Therapy

Abrupt cessation of tizanidine can lead to a withdrawal syndrome, particularly in patients who have been on high doses (20-36 mg/day) for extended periods (9 weeks or more) or who are also taking narcotics.[7] This syndrome is characterized by rebound hypertension, tachycardia, and hypertonia (a worsening of spasticity).[3] To mitigate this risk, the dose should be tapered gradually upon discontinuation. A typical tapering schedule involves decreasing the daily dose by 2 mg to 4 mg each day until the medication is stopped completely.[16]

Safety Profile, Tolerability, and Risk Management

While tizanidine can be an effective agent for spasticity, its use is associated with a distinct profile of adverse effects and risks that require careful management, monitoring, and patient counseling.

Adverse Drug Reactions (ADRs)

The adverse effects of tizanidine are largely predictable extensions of its pharmacology as a central α2​-adrenergic agonist and CNS depressant. The incidence and severity of many of these effects are dose-related.

Common ADRs

The most frequently encountered side effects in clinical trials are often the primary reasons for dose limitation or discontinuation.

• Dry Mouth (Xerostomia): This is the most common adverse effect, reported in up to 49% of patients in controlled studies.[7]
• Somnolence/Drowsiness/Sedation: A very common effect, reported in up to 48% of patients. This can significantly impair daily activities, including driving and operating machinery.[7]
• Asthenia (Weakness/Fatigue): Reported in up to 41% of patients, this can be difficult to distinguish from the underlying weakness associated with the patient's neurological condition.[7]
• Dizziness: Occurs in approximately 16% of patients and can contribute to the risk of falls, especially in combination with hypotension.[7]

Other relatively common adverse reactions include constipation, nervousness, vomiting, urinary tract infection, and speech disorders.[1]

Table 3: Incidence of Common Adverse Reactions from Controlled Clinical Trials

Adverse Reaction	Tizanidine Incidence (%)	Placebo Incidence (%)	Source(s)
Dry Mouth	49	10	7
Somnolence	48	10	7
Asthenia*	41	16	7
Dizziness	16	4	7
Urinary Tract Infection	>2	< Tizanidine Incidence	7
Constipation	>2	< Tizanidine Incidence	7
Vomiting	>2	< Tizanidine Incidence	7
Speech Disorder	>2	< Tizanidine Incidence	7
*Asthenia includes weakness, fatigue, and/or tiredness.

Serious ADRs

Although less common, tizanidine is associated with several potentially serious adverse reactions that require immediate clinical attention.

• Hypotension: Dose-related decreases in blood pressure are common. This can manifest as orthostatic hypotension, lightheadedness, and, in some cases, syncope (fainting).[1]
• Hepatotoxicity: Tizanidine has been linked to rare instances of acute liver injury. This can range from asymptomatic elevations in serum aminotransferases (ALT/SGPT) to more severe cases of hepatitis. Very rare cases of fatal, fulminant liver failure have been reported in post-marketing surveillance.[4]
• Hallucinations/Psychosis: Formed visual hallucinations or delusions have been reported in approximately 3% of patients in controlled clinical trials. Most patients were aware that the events were not real, but in some cases, psychosis developed.[1]
• Cardiovascular Effects: In addition to hypotension, bradycardia (slow heart rate) can occur. Rare post-marketing reports have also noted QT prolongation, which could increase the risk of serious cardiac arrhythmias.[1]
• Hypersensitivity Reactions: Serious allergic reactions, including anaphylaxis and angioedema (swelling of the face, lips, and throat), have been reported.[18]

Warnings and Precautions

To mitigate these risks, specific warnings and monitoring practices are recommended.

• Liver Injury: Monitoring of liver function tests (ALT, AST) is recommended at baseline, one month after the maximum tolerated dose is achieved, and periodically thereafter, especially for patients on long-term or high-dose therapy. The drug should be discontinued if evidence of significant liver injury occurs.[4]
• Sedation: Patients must be counseled about the high potential for sedation and warned against performing hazardous tasks such as driving until they know how the medication affects them. The sedative effects are additive with other CNS depressants.[7]
• Hypotension: Blood pressure should be monitored, particularly during the initial dose-titration period and in patients who are also taking antihypertensive medications.[4]

Contraindications

The use of tizanidine is strictly contraindicated in two specific situations:

1. Concomitant use with potent inhibitors of CYP1A2, such as fluvoxamine and ciprofloxacin, due to the risk of a massive increase in tizanidine plasma concentrations and severe adverse effects.[17]
2. Patients with a known hypersensitivity to tizanidine or any of the excipients in the formulation.[4]

Use in Specific Populations

Dosing and monitoring must be adjusted for certain patient populations.

• Renal Impairment: In patients with significant renal impairment (creatinine clearance <25 mL/min), the clearance of tizanidine is reduced by more than 50%. This necessitates the use of lower starting doses and a more gradual titration schedule, with close monitoring for signs of toxicity (e.g., excessive sedation, dry mouth, dizziness).[3]
• Hepatic Impairment: Given its extensive hepatic metabolism, tizanidine should be used with caution in patients with any degree of liver dysfunction. It is generally not recommended for use in patients with severe hepatic impairment.[4]
• Geriatric Use: Elderly patients exhibit reduced clearance of tizanidine (a four-fold decrease has been reported) and are more susceptible to its adverse effects. They are also more likely to have co-morbid renal impairment. Consequently, lower initial doses and cautious titration are warranted in this population.[18]
• Pregnancy and Lactation: Animal reproduction studies have suggested a potential for fetal harm. As there are no adequate and well-controlled studies in pregnant women, tizanidine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known if tizanidine is excreted in human breast milk, but because it is a lipid-soluble drug, it is likely to be. Caution is advised when administering to a nursing woman.[3]

Clinically Significant Drug-Drug Interactions

The potential for drug-drug interactions (DDIs) is arguably the most critical safety concern associated with tizanidine therapy. These interactions are driven primarily by its singular metabolic pathway and are augmented by its pharmacodynamic effects. Understanding this DDI profile allows for a clear stratification of risk, from combinations that are absolutely contraindicated to those that require enhanced vigilance.

The Central Role of CYP1A2 Metabolism and its Clinical Consequences

As previously established, tizanidine's clearance from the body is almost entirely dependent on metabolism by the cytochrome P450 enzyme CYP1A2.[8] This heavy reliance on a single enzyme makes tizanidine exceptionally vulnerable to any co-administered drug that inhibits this pathway. Inhibition of CYP1A2 can block the metabolism of tizanidine, leading to a rapid and dramatic accumulation of the drug in the plasma. This elevated exposure directly amplifies all of its pharmacological effects, most dangerously its hypotensive and sedative properties, transforming a therapeutic dose into a toxic one.[9]

Contraindicated Combinations: Potent CYP1A2 Inhibitors

The magnitude of the interaction with potent CYP1A2 inhibitors is so great that their concurrent use with tizanidine is considered absolutely contraindicated.

• Fluvoxamine: This selective serotonin reuptake inhibitor (SSRI) is a potent inhibitor of CYP1A2. Clinical studies have demonstrated that co-administration of fluvoxamine with tizanidine increases the tizanidine AUC (a measure of total drug exposure) by an astounding 33-fold and the Cmax​ by 12-fold.[1] This massive increase in concentration results in clinically significant and potentially dangerous hypotension and bradycardia.[8]
• Ciprofloxacin: This widely used fluoroquinolone antibiotic is also a potent inhibitor of CYP1A2. Concomitant use has been shown to increase the tizanidine AUC by 10-fold.[9] This substantial increase also poses a high risk of severe adverse events, leading to its contraindicated status.[17]

Interactions Requiring Caution: Moderate and Weak CYP1A2 Inhibitors

While not absolutely contraindicated, the co-administration of tizanidine with less potent inhibitors of CYP1A2 still requires significant caution, as these drugs can increase tizanidine levels and heighten the risk of adverse effects.[42] Dose reduction and close clinical monitoring for hypotension, bradycardia, and excessive sedation are warranted. Examples of such drugs include:

• Oral Contraceptives: Combined hormonal contraceptives are moderate inhibitors of CYP1A2 and can reduce tizanidine clearance by approximately 50%.[9]
• Other Fluoroquinolones: Antibiotics such as moxifloxacin and levofloxacin may also inhibit CYP1A2 to a lesser extent than ciprofloxacin.[1]
• Antiarrhythmics: Agents like amiodarone.[43]
• H2-Receptor Antagonists: Cimetidine and famotidine.[42]
• Other Agents: Acyclovir, zileuton, and ticlopidine.[42]

Pharmacodynamic Interactions (Additive Effects)

Separate from metabolic interactions, tizanidine can interact with other drugs that have similar physiological effects, leading to an additive or synergistic potentiation of these effects.

• CNS Depressants: The most common pharmacodynamic interaction involves other CNS depressants. The sedative and CNS-depressant effects of tizanidine are additive with those of alcohol, benzodiazepines, opioids, tricyclic antidepressants, and other sedating medications. Combining these agents significantly increases the risk of profound somnolence, dizziness, cognitive impairment, and respiratory depression.[1] Furthermore, alcohol can also increase the AUC of tizanidine by approximately 20%, adding a pharmacokinetic component to this interaction.[17]
• Antihypertensive Agents: The hypotensive effect of tizanidine is additive with that of other blood pressure-lowering drugs, including diuretics and especially other α2​-adrenergic agonists like clonidine or guanfacine. Co-administration increases the risk of clinically significant hypotension, orthostasis, and bradycardia.[7] The use of tizanidine with other α2​-agonists is generally not recommended.[7]

Table 4: Guide to Clinically Significant Drug Interactions with Tizanidine

Interacting Drug/Class	Mechanism of Interaction	Clinical Consequence	Management Recommendation	Source(s)
CONTRAINDICATED
Fluvoxamine	Potent CYP1A2 Inhibition	33-fold increase in tizanidine AUC; severe hypotension, bradycardia, sedation.	Contraindicated.	1
Ciprofloxacin	Potent CYP1A2 Inhibition	10-fold increase in tizanidine AUC; severe hypotension, sedation.	Contraindicated.	9
MAJOR INTERACTION - USE WITH CAUTION
Other CYP1A2 Inhibitors (e.g., oral contraceptives, amiodarone, cimetidine, other fluoroquinolones)	Moderate/Weak CYP1A2 Inhibition	Increased tizanidine levels; increased risk of hypotension, bradycardia, sedation.	Use with caution. Consider lower tizanidine dose and monitor closely for adverse effects.	17
Alcohol	Additive CNS Depression; Pharmacokinetic (increased AUC)	Markedly increased sedation, dizziness, psychomotor impairment; risk of hypotension.	Avoid concomitant use. Counsel patients on risks.	1
Benzodiazepines, Opioids, other CNS Depressants	Additive CNS Depression	Increased sedation, cognitive impairment, risk of respiratory depression.	Use with caution. Monitor for excess sedation. Consider dose reduction of one or both agents.	7
Antihypertensive Agents (including other α2​-agonists)	Additive Hypotensive Effect	Increased risk of hypotension, orthostasis, and bradycardia.	Use with caution. Monitor blood pressure closely, especially during dose titration. Avoid use with other α2​-agonists.	17

Overdose and Toxicity Management

An overdose of tizanidine is a serious medical event that requires prompt recognition and supportive care. The clinical presentation is a direct and severe extension of the drug's known pharmacological effects.

Clinical Presentation of Overdose

The signs and symptoms of tizanidine toxicity primarily involve depression of the central nervous, cardiovascular, and respiratory systems.[44] The most common features observed in cases of overdose include:

• Central Nervous System Depression: This is the most prominent feature, ranging in severity from lethargy, profound drowsiness, and confusion to stupor and deep coma.[1] In a retrospective review of 45 overdose cases, lethargy was present in 84% of patients.[1] Agitation and vomiting may also occur in some cases.[1]
• Cardiovascular Depression: Bradycardia (slow heart rate) and hypotension are common cardiovascular manifestations. Hypotension can be severe and is a significant cause of morbidity.[1]
• Respiratory Depression: In severe overdoses, respiratory drive can be suppressed, leading to slow or shallow breathing and, potentially, respiratory failure.[16]

The severity of the overdose correlates with the ingested dose. While the maximum recommended daily dose is 36 mg, the mean ingested dose in one reported case series was 72 mg.[1] Coma has been reported with ingestions in the range of 60 to 120 mg.[46] The risk of severe toxicity is significantly increased by the co-ingestion of other CNS depressants, such as alcohol, opioids, or benzodiazepines.[44]

Management of Overdose

There is no specific antidote for tizanidine overdose. Therefore, management is entirely supportive and symptomatic, focused on maintaining vital functions until the drug is eliminated from the body.[44]

• Airway Management: The immediate priority is to assess and secure the patient's airway. Ensuring adequate ventilation and oxygenation is critical, and endotracheal intubation may be required for patients with significant respiratory depression or inability to protect their airway.[44]
• Cardiovascular Support: Hypotension should be managed with intravenous fluid resuscitation. If hypotension persists despite adequate fluid administration, vasopressor agents (e.g., norepinephrine) may be necessary to maintain adequate organ perfusion.[44] Bradycardia may require intervention if it is hemodynamically significant.
• Decontamination: In cases of a large, recent ingestion, gastrointestinal decontamination with gastric lavage may be considered, although its utility diminishes with time since ingestion.[45] Activated charcoal may also be administered to decrease drug absorption.
• Monitoring: Continuous monitoring of vital signs (heart rate, blood pressure, respiratory rate, oxygen saturation), cardiac rhythm via electrocardiogram (ECG), and neurological status (level of consciousness) is essential throughout the management period.[44]
• Ineffective Interventions: The opioid antagonist naloxone is not effective in reversing tizanidine-induced CNS or respiratory depression and is not indicated unless a concomitant opioid overdose is suspected.[44]

With prompt and aggressive supportive care, the prognosis for tizanidine overdose is generally good. Most patients recover fully within 1 to 3 days without lasting sequelae.[44]

Regulatory and Commercial Landscape

Tizanidine is an established medication with a long history of clinical use and is available in numerous countries worldwide under various brand names.

Regulatory History

• United States (FDA): Tizanidine was first approved for medical use in the United States by the FDA in 1996.[1] The initial New Drug Application (NDA 20-397), sponsored by Athena Neurosciences, was for the 4 mg tablet formulation of Zanaflex, approved on November 27, 1996, for the management of spasticity.[39] A 2 mg tablet was subsequently approved on February 4, 2000.[39] A new formulation, Zanaflex Capsules, was approved under NDA 21-447 on August 29, 2002.[39] Following patent expiry, numerous generic versions of both tablets and capsules have been approved and are widely available.[1]
• Europe (EMA): Tizanidine is not centrally authorized by the European Medicines Agency (EMA) but is approved on a national basis in many individual member states of the European Union.[50] The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) conducts periodic safety update report single assessments (PSUSAs) for tizanidine, which involves a collective review of safety data from all nationally authorized products containing the substance, ensuring consistent safety monitoring across the EU.[50]
• Canada (Health Canada): Tizanidine is approved and marketed in Canada for the management of spasticity. The original market date for the generic product APO-TIZANIDINE was November 17, 2004.[52] Numerous other generic versions, such as MINT-TIZANIDINE, are also available.[37] Health Canada provides detailed Product Monographs for these products, outlining their indications, contraindications, and safety information.[36]

Commercial Information

• Brand Names: While widely available as a generic, tizanidine is marketed under several brand names globally. The most common include Zanaflex (United States, Canada), Sirdalud (many countries in Europe, Latin America, and Asia), and Ternelin (Japan).[1] In the US, a newer brand name, Ontralfy, is also available.[3] A comprehensive list of international brand names includes numerous combination products, often with NSAIDs like aceclofenac, diclofenac, or nimesulide, particularly in markets like India.[55]
• Prescription Status: Tizanidine is a prescription-only medication in all major regulatory jurisdictions, including the United States (℞-only) and the United Kingdom (POM - Prescription Only Medicine).[1] In the United States, it is not classified as a controlled substance by the Drug Enforcement Administration (DEA).[31]
• Usage Statistics: Tizanidine is a very commonly prescribed medication. In 2023, it was the 81st most frequently prescribed drug in the United States, with over 8.2 million prescriptions dispensed.[1] This high volume of use underscores the importance of widespread clinical understanding of its properties and risks.

Expert Synthesis and Concluding Remarks

Tizanidine is a well-established and effective centrally acting skeletal muscle relaxant that occupies a distinct and valuable niche in the pharmacological management of spasticity. Its clinical profile is defined by a unique interplay between its mechanism of action as an α2​-adrenergic agonist, its short duration of action, and its singular, vulnerable metabolic pathway. A comprehensive appreciation of these three pillars is essential for harnessing its therapeutic benefits while mitigating its significant inherent risks.

Tizanidine's Clinical Niche

The defining clinical characteristic of tizanidine is its short duration of action, a direct consequence of its rapid absorption and short elimination half-life of approximately 2.5 hours. This pharmacokinetic property positions tizanidine not as a tool for maintaining a constant, basal level of muscle relaxation, but rather as an agent for providing intermittent, targeted relief. Its ideal application is for patients who experience disabling spasticity that interferes with specific, predictable daily activities, such as morning hygiene, transfers, or participation in physical therapy sessions. When prescribed on this "as-needed" basis, tizanidine allows for the maximization of functional improvement while minimizing the cumulative burden of its primary side effect, sedation. This contrasts with other agents like baclofen, which may be more suited for patients requiring more continuous spasticity control throughout the day.

The Double-Edged Sword of CYP1A2 Metabolism

The most critical aspect governing the safe use of tizanidine is its near-total reliance on the cytochrome P450 1A2 enzyme for its metabolic clearance. This pharmacokinetic feature is a double-edged sword. While it provides a predictable elimination pathway, it also creates a profound vulnerability that demands a higher level of clinical vigilance than for many other commonly prescribed medications. The potential for a 10- to 33-fold increase in drug exposure when combined with common medications like ciprofloxacin or fluvoxamine is a predictable and severe danger. This interaction is not a subtle modulation of effect but a transformation of a therapeutic dose into a potentially life-threatening overdose. Therefore, the absolute contraindication against the use of tizanidine with potent CYP1A2 inhibitors is the single most important safety principle for prescribers to observe.

Final Recommendations for Prescribers

Based on a comprehensive analysis of its pharmacological, clinical, and safety data, the following recommendations are crucial for the optimal use of tizanidine:

1. Screening is Non-Negotiable: Before initiating tizanidine, an exhaustive medication reconciliation is mandatory. The prescriber must specifically and actively screen for the concomitant use of potent CYP1A2 inhibitors, particularly fluvoxamine and ciprofloxacin. This step is a non-negotiable prerequisite for safe prescribing.
2. Patient Education is Paramount: Effective patient counseling is central to mitigating the risks of tizanidine therapy. Patients must be educated on several key points: the critical importance of consistency with respect to food intake; the fact that tablet and capsule formulations are not interchangeable; the significant risks of combining the medication with alcohol and other CNS depressants; and the necessity of a gradual dose taper upon discontinuation to avoid withdrawal symptoms.
3. Adherence to "Start Low, Go Slow": The principle of initiating therapy with a low dose (e.g., 2 mg) and titrating upwards slowly is essential. This approach allows for the individualization of therapy to find the lowest effective dose, thereby balancing the desired reduction in spasticity against the predictable and dose-limiting side effects of sedation, dizziness, and hypotension.
4. Right Patient, Right Purpose: Tizanidine is a highly effective therapeutic agent when used appropriately. Its greatest value is realized when it is prescribed for its intended purpose—providing short-acting, intermittent relief of spasticity—in a patient for whom the risks have been carefully assessed and managed. When used with this level of knowledge and caution, tizanidine remains an indispensable tool in the armamentarium for treating neurological spasticity.

Works cited

1. Tizanidine - Wikipedia, accessed September 8, 2025, https://en.wikipedia.org/wiki/Tizanidine
2. Tizanidine: neuropharmacology and mechanism of action - PubMed, accessed September 8, 2025, https://pubmed.ncbi.nlm.nih.gov/7970012/
3. Tizanidine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 8, 2025, https://go.drugbank.com/drugs/DB00697
4. Tizanidine - StatPearls - NCBI Bookshelf, accessed September 8, 2025, https://www.ncbi.nlm.nih.gov/books/NBK519505/
5. go.drugbank.com, accessed September 8, 2025, https://go.drugbank.com/drugs/DB00697#:~:text=Tizanidine%20reduces%20spasticity%20by%20causing,that%20leads%20to%20muscle%20spasm.
6. Tizanidine Patient Tips: 7 things you should know - Drugs.com, accessed September 8, 2025, https://www.drugs.com/tips/tizanidine-patient-tips
7. ZANAFLEX Label - accessdata.fda.gov, accessed September 8, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021447s011_020397s026lbl.pdf
8. PRESCRIBING INFORMATION Zanaflex Capsules™ 1 (tizanidine hydrochloride) 2 Zanaflex® Tablets 3 (tizanidine hydrochloride) 4 - accessdata.fda.gov, accessed September 8, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020397s021,021447s002lbl.pdf
9. Tizanidine interactions - The Pharmaceutical Journal, accessed September 8, 2025, https://pharmaceutical-journal.com/article/ld/tizanidine-interactions
10. Tizanidine | C9H8ClN5S | CID 5487 - PubChem, accessed September 8, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Tizanidine
11. Tizanidine - the NIST WebBook - National Institute of Standards and Technology, accessed September 8, 2025, https://webbook.nist.gov/cgi/cbook.cgi?ID=51322-75-9
12. CAS 51322-75-9 Tizanidine - BOC Sciences, accessed September 8, 2025, https://www.bocsci.com/tizanidine-cas-51322-75-9-item-70116.html
13. Zanaflex (Tizanidine): Side Effects, Uses, Dosage, Interactions, Warnings - Rx List, accessed September 8, 2025, https://www.rxlist.com/zanaflex-drug.htm
14. What is the mechanism of Tizanidine Hydrochloride? - Patsnap Synapse, accessed September 8, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-tizanidine-hydrochloride
15. Tizanidine: Muscle Relaxer Uses, Warnings, Side Effects, Dosage - MedicineNet, accessed September 8, 2025, https://www.medicinenet.com/tizanidine/article.htm
16. Tizanidine: MedlinePlus Drug Information, accessed September 8, 2025, https://medlineplus.gov/druginfo/meds/a601121.html
17. Tizanidine | 51322-75-9 - ChemicalBook, accessed September 8, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9670538.htm
18. Tizanidine (Zanaflex): Uses & Side Effects - Cleveland Clinic, accessed September 8, 2025, https://my.clevelandclinic.org/health/drugs/20343-tizanidine-capsules-or-tablets
19. Tizanidine Dosage Guide: Adjustments and How to Take It - GoodRx, accessed September 8, 2025, https://www.goodrx.com/tizanidine/dosage
20. tizanidine: Dosing, contraindications, side effects, and pill pictures - epocrates online, accessed September 8, 2025, https://www.epocrates.com/online/drugs/1422/tizanidine
21. pharmaceutical-journal.com, accessed September 8, 2025, https://pharmaceutical-journal.com/article/ld/tizanidine-interactions#:~:text=Tizanidine%20is%20metabolised%20substantially%20by,therefore%20increase%20its%20adverse%20effects.
22. A Disproportionality Analysis of Drug–Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS) - ProQuest, accessed September 8, 2025, https://search.proquest.com/openview/929116fc7f3f0d02634f0e59a50bfc25/1.pdf?pq-origsite=gscholar&cbl=32187
23. Tizanidine powder - FEPBlue.com, accessed September 8, 2025, https://www.fepblue.org/-/media/PDFs/Medical-Policies/2024/January/Pharmacy-Policies-Dec-2023/Remove-and-Replace/5_75_012-Tizanidine-powder.pdf
24. Muscle Spasms and More: 7 Tizanidine Uses - GoodRx, accessed September 8, 2025, https://www.goodrx.com/tizanidine/tizanidine-uses
25. www.ncbi.nlm.nih.gov, accessed September 8, 2025, https://www.ncbi.nlm.nih.gov/books/NBK519505/#:~:text=It%20is%20also%20prescribed%20off,to%20assist%20with%20analgesic%20withdrawal.
26. Tizanidine Completed Phase 4 Trials for Upper Limb Spasticity Treatment - DrugBank, accessed September 8, 2025, https://go.drugbank.com/drugs/DB00697/clinical_trials?conditions=DBCOND0036871&phase=4&purpose=treatment&status=completed
27. Tizanidine Completed Phase 4 Trials for Lower Back Pain Treatment | DrugBank Online, accessed September 8, 2025, https://go.drugbank.com/drugs/DB00697/clinical_trials?conditions=DBCOND0030634&phase=4&purpose=treatment&status=completed
28. Tizanidine Completed Phase N/A Trials for Arthritis / Tendonitis / Synovitis / Headache / Nerve Root Disorder / Gout Flares / Muscle Spasms / Migraine - DrugBank, accessed September 8, 2025, https://go.drugbank.com/drugs/DB00697/clinical_trials?conditions=DBCOND0016433%2CDBCOND0052747%2CDBCOND0017979%2CDBCOND0017962%2CDBCOND0053860%2CDBCOND0017502%2CDBCOND0016437%2CDBCOND0015531&status=completed
29. Tizanidine: Side Effects, Uses, Dosage, Interactions, Warnings - Rx List, accessed September 8, 2025, https://www.rxlist.com/tizanidine/generic-drug.htm
30. Tizanidine: Package Insert / Prescribing Information - Drugs.com, accessed September 8, 2025, https://www.drugs.com/pro/tizanidine.html
31. Tizanidine Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed September 8, 2025, https://www.drugs.com/dosage/tizanidine.html
32. Tizanidine and pain management | JPR - Dove Medical Press, accessed September 8, 2025, https://www.dovepress.com/tizanidine-advances-in-pharmacology--therapeutics-and-drug-formulation-peer-reviewed-fulltext-article-JPR
33. Tizanidine Uses, Dosage, Side Effects - Drugs.com, accessed September 8, 2025, https://www.drugs.com/tizanidine.html
34. Reference ID: 5484759 - accessdata.fda.gov, accessed September 8, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020397s029,021447s017lbl.pdf
35. Tizanidine Side Effects: Common, Severe, Long Term - Drugs.com, accessed September 8, 2025, https://www.drugs.com/sfx/tizanidine-side-effects.html
36. Tizanidine Hydrochloride Tablets USP 2 mg and 4 mg Tizanidine Antispastic Agent APOTEX INC 150 Signet Drive Toronto, Ontario Canada M9L 1T9 - PRODUCT MONOGRAPH, accessed September 8, 2025, https://pdf.hres.ca/dpd_pm/00073035.PDF
37. PRODUCT MONOGRAPH PrMINT-TIZANIDINE, accessed September 8, 2025, https://pdf.hres.ca/dpd_pm/00070180.PDF
38. Zanaflex (tizanidine) dosing, indications, interactions, adverse effects, and more, accessed September 8, 2025, https://reference.medscape.com/drug/zanaflex-tizanidine-343071
39. 21-447 Zanaflex Medical Review Part 1 - accessdata.fda.gov, accessed September 8, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-447_Zanaflex_Medr_P1.pdf
40. Tizanidine (oral route) - Side effects & dosage - Mayo Clinic, accessed September 8, 2025, https://www.mayoclinic.org/drugs-supplements/tizanidine-oral-route/description/drg-20066921
41. Tizanidine, a Frequently Used Muscle Relaxant, Is Associated with Severe Hypotension: Role of Cytochrome P450 1A2 Inhibition in Routine Clinical Practice - ACR abstract, accessed September 8, 2025, https://acrabstracts.org/abstract/tizanidine-a-frequently-used-muscle-relaxant-is-associated-with-severe-hypotension-role-of-cytochrome-p450-1a2-inhibition-in-routine-clinical-practice/
42. ZANAFLEX® (tizanidine hydrochloride) capsules, for oral use - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed September 8, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021447s015lbl.pdf
43. The Top 7 Tizanidine Interactions to Avoid - GoodRx, accessed September 8, 2025, https://www.goodrx.com/tizanidine/interactions
44. Can you overdose on tizanidine (muscle relaxant)? - Dr.Oracle AI, accessed September 8, 2025, https://www.droracle.ai/articles/209823/can-you-over-do-tizanidine
45. 21-447 Zanaflex Medical Review Part 2 - accessdata.fda.gov, accessed September 8, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-447_Zanaflex_Medr_P2.pdf
46. SKELETAL MUSCLE RELAXANTS | Poisoning & Drug Overdose, 7e | AccessMedicine, accessed September 8, 2025, https://accessmedicine.mhmedical.com/content.aspx?bookid=2284§ionid=248385464
47. Generic Zanaflex Availability - Drugs.com, accessed September 8, 2025, https://www.drugs.com/availability/generic-zanaflex.html
48. Zanaflax (Tizanidine HCL) Oral Tabs 4MG - accessdata.fda.gov, accessed September 8, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020397Orig1s000rev.pdf
49. Drug Approval Package: Tizanidine NDA #021447 - accessdata.fda.gov, accessed September 8, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-447_Zanaflex.cfm
50. PSUSA/00002977/201912 - periodic safety update report single assessment, accessed September 8, 2025, https://www.ema.europa.eu/en/medicines/psusa/psusa-00002977-201912
51. National registers of authorised medicines | European Medicines Agency (EMA), accessed September 8, 2025, https://www.ema.europa.eu/en/medicines/national-registers-authorised-medicines
52. From Health Canada - Product information, accessed September 8, 2025, https://produits-sante.canada.ca/dpd-bdpp/info?lang=eng&code=74515
53. Tizanidine - Memorial Sloan Kettering Cancer Center, accessed September 8, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/adult/tizanidine
54. Consumer Information for: APO-TIZANIDINE - Drug and Health Products Portal, accessed September 8, 2025, https://dhpp.hpfb-dgpsa.ca/dhpp/resource/74515/consumer-information
55. Tizanidine (International database) - Drugs.com, accessed September 8, 2025, https://www.drugs.com/international/tizanidine.html
56. Tizanidine - Drug Usage Statistics, ClinCalc DrugStats Database, accessed September 8, 2025, https://clincalc.com/drugstats/Drugs/Tizanidine